This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Chesapeake Urology Associates Launches Prostate Cancer Website

BALTIMORE, April 2, 2013 /PRNewswire/ --  Chesapeake Urology Associates, PA, the premier urology practice in Maryland and the Mid-Atlantic region, has launched a comprehensive website devoted strictly to its Prostate Cancer Care Program.

The site, with a URL of, is an easy-to-access body of information that was built for prostate cancer patients and consumers alike.  It provides detail on how prostate cancer is diagnosed, treatment options for different stages of the disease, answers to frequently asked questions, a glossary of terms and recommended questions to ask at a physician appointment. This informational source gives patients more detail and perspective about prostate cancer, and enables them to select the treatment pathway that is right for them.

In addition, the site outlines the Chesapeake Urology Prostate Cancer Care Program, including its mission, experts, clinical trials, support networks and patient resources. There are also patient stories, blogs and information about the Zero Prostate Cancer Challenge, which features a 5K run, a 1 mile walk and free prostate cancer screenings held each September during National Prostate Cancer Awareness Month.

"The new website serves as an informational tool to help people learn more about prostate cancer and the high level of care provided by Chesapeake Urology physicians and staff," says Benjamin Lowentritt, M.D., director of Chesapeake Urology's Prostate Cancer Care program. "It also demonstrates Chesapeake Urology's leadership, experience and commitment to the fight against prostate cancer."

According to Dr. Lowentritt, 1 in every 6 men will get prostate cancer sometime in his life. About 241,740 new cases of prostate cancer were diagnosed in 2012 - on par with breast cancer. In addition, the chances of getting prostate cancer are 1 in 3 if you have just one close relative (father, brother) with the disease. The risk is 83 percent with two close relatives and 97 percent with three.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs